Arcus Biosciences, Inc. (RCUS)
After hours:
| Previous close | 15.50 |
| Open | 15.97 |
| Bid | 15.40 x 1000 |
| Ask | 17.16 x 800 |
| Day's range | 15.49 - 16.36 |
| 52-week range | 12.95 - 25.47 |
| Volume | |
| Avg. volume | 769,750 |
| Market cap | 1.428B |
| Beta (5Y monthly) | 0.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.15 |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 38.50 |
- Business Wire
Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024
HAYWARD, Calif., May 02, 2024--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Bank of America Healthcare Conference in Las Vegas, NV. The fireside chat will take place on Thursday, May 16th, 2024 at 10:00am PT.
ZacksAdverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Adverum Biotechnologies (ADVM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksWill Arcus Biosciences, Inc. (RCUS) Report Negative Earnings Next Week? What You Should Know
Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
